

Datasheet

CDKN1B (phospho T198) polyclonal antibody

Catalog Number: PAB4921

Regulation Status: For research use only (RUO)

Product Description: Rabbit polyclonal antibody raised against synthetic phosphopeptide of CDKN1B.

Immunogen: Synthetic phosphopeptide (conjugated with KLH) corresponding to residues surrounding T198 of human CDKN1B.

Host: Rabbit

Reactivity: Human

Applications: Dot-Pep, ELISA
(See our web site product page for detailed applications information)

Protocols: See our web site at
<http://www.abnova.com/support/protocols.asp> or product page for detailed protocols

Form: Liquid

Purification: Protein A purification

Recommend Usage: ELISA (1:1000)
Dot Blot (1:500)
The optimal working dilution should be determined by the end user.

Storage Buffer: In PBS (0.09% sodium azide)

Storage Instruction: Store at 4°C. For long term storage store at -20°C.
Aliquot to avoid repeated freezing and thawing.

Entrez GeneID: 1027

Gene Symbol: CDKN1B

Gene Alias: CDKN4, KIP1, MEN1B, MEN4, P27KIP1

Gene Summary: This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds

to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. [provided by RefSeq]

References:

1. Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. Kawamata N, Inagaki N, Mizumura S, Sugimoto KJ, Sakajiri S, Ohyanagi-Hara M, Oshimi K. Eur J Haematol. 2005 May;74(5):424-9.
2. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA, Montiel-Duarte C, Rifon J, Perez-Calvo J, Arbona C, Prosper F, Perez-Roger I. Cancer Res. 2005 Apr 15;65(8):3264-72.
3. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. J Biol Chem. 2005 Apr 15;280(15):15148-57. Epub 2005 Feb 10.